Ra Capital Management, L.P. Sells 135,201 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 135,201 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59. Following the completion of the transaction, the director owned 3,936,436 shares in the company, valued at $65,305,473.24. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Trading Down 0.8%

Vor Biopharma stock opened at $15.47 on Friday. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The company has a market cap of $755.71 million, a PE ratio of -0.04 and a beta of 1.92. The company’s 50-day moving average is $14.41 and its two-hundred day moving average is $17.06.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VOR. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Jefferies Financial Group began coverage on Vor Biopharma in a research note on Monday, March 30th. They issued a “buy” rating and a $50.00 price target on the stock. Wedbush increased their price target on Vor Biopharma to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $50.67.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in VOR. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma in the 4th quarter valued at $36,000. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the period. XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth $66,000. Chung Wu Investment Group LLC acquired a new stake in Vor Biopharma during the 4th quarter worth $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in Vor Biopharma during the 4th quarter worth $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).